SLC5A2 and type 2 diabetes mellitus: This is the first demonstration using 18F-Me-4FDG-PET of the potential of renal SGLT2-related excretion in predicting long-term glycemic control response following SGLT2 inhibitor treatment in type 2 diabetes [48].